1 01/12/2022 30/11/2023 2023-11-30 false false false false false false false true false false true false false false false false false false No description of principal activities is disclosed 2022-12-01 Sage Accounts Production 23.0 - FRS102_2023 xbrli:pure xbrli:shares iso4217:GBP 12313140 2022-12-01 2023-11-30 12313140 2023-11-30 12313140 2022-11-30 12313140 2021-12-01 2022-11-30 12313140 2022-11-30 12313140 2021-11-30 12313140 bus:Director1 2022-12-01 2023-11-30 12313140 core:WithinOneYear 2023-11-30 12313140 core:WithinOneYear 2022-11-30 12313140 core:ShareCapital 2023-11-30 12313140 core:ShareCapital 2022-11-30 12313140 core:RetainedEarningsAccumulatedLosses 2023-11-30 12313140 core:RetainedEarningsAccumulatedLosses 2022-11-30 12313140 core:CostValuation core:Non-currentFinancialInstruments 2023-11-30 12313140 core:Non-currentFinancialInstruments 2023-11-30 12313140 core:Non-currentFinancialInstruments 2022-11-30 12313140 bus:SmallEntities 2022-12-01 2023-11-30 12313140 bus:AuditExempt-NoAccountantsReport 2022-12-01 2023-11-30 12313140 bus:SmallCompaniesRegimeForAccounts 2022-12-01 2023-11-30 12313140 bus:PrivateLimitedCompanyLtd 2022-12-01 2023-11-30 12313140 bus:AbridgedAccounts 2022-12-01 2023-11-30
Company registration number: 12313140
Medellence Limited
Information for filing with the registrar
30 November 2023
Medellence Limited
Contents
Abridged statement of financial position
Notes to the financial statements
Medellence Limited
Abridged statement of financial position
30 November 2023
2023 2022
Note £ £ £ £
Fixed assets
Investments 5 102 102
_______ _______
102 102
Current assets
Debtors 155,658 156,648
Cash at bank and in hand 3,417 3,417
_______ _______
159,075 160,065
Creditors: amounts falling due
within one year ( 928) ( 928)
_______ _______
Net current assets 158,147 159,137
_______ _______
Total assets less current liabilities 158,249 159,239
_______ _______
Net assets 158,249 159,239
_______ _______
Capital and reserves
Called up share capital 100 100
Profit and loss account 158,149 159,139
_______ _______
Shareholders funds 158,249 159,239
_______ _______
For the year ending 30 November 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the abridged statement of comprehensive income has not been delivered.
All of the members have consented to the preparation of the abridged statement of comprehensive income and the abridged statement of financial position for the current year ending 30 November 2023 in accordance with Section 444(2A) of the Companies Act 2006.
These financial statements were approved by the board of directors and authorised for issue on 30 August 2024 , and are signed on behalf of the board by:
Mrs E Markaryan
Director
Company registration number: 12313140
Medellence Limited
Notes to the financial statements
Year ended 30 November 2023
1. General information
The company is a private company limited by shares, registered in the UK. The address of the registered office is Medellence Limited, 7 Bell Yard, London, England, WC2A 2JR.
2. Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Fixed asset investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses. Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Impairment
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 1 (2022: 1 ).
5. Investments
£
Cost
At 1 December 2022 and 30 November 2023 102
_______
Impairment
At 1 December 2022 and 30 November 2023 -
_______
Carrying amount
At 30 November 2023 102
_______
At 30 November 2022 102
_______
Investments in group undertakings
Registered office Class of share Percentage of shares held
Participating interest
Enteromed Limited England Ordinary 100
Doctor Gut Limited England Ordinary 100
6. Related party transactions
Mrs E Markaryan is director and 100% shareholder of the company.At the year end the company owed to £178 (2022 : £178) for expenses paid on its behalf. Medellence Limited is 100% shareholder of Enteromed Limited. The company received Management fees of Nil (2022 : Nil) during the period. At the year end the company owed £60,951 (2022 : £61,041) from Enteromed Limited. Medellence Limited is also 100% shareholder of Doctor Gut limited. At the year end the company owed £95,607 (2022 : £95,607) from Doctor Gut limited.
7. Controlling party
The controlling party is Mrs E Markaryan .
8. Parent-subsidary relationship
The company holds 100% of the equity shares issued by Enteromed Limited. The subsidiary's registered office address is: 85 Great Portland Street,First Floor,London,England,W1W 7LT The company also holds 100% of the equity shares issued by Doctor Gut Limited. The subsidiary's registered office address is: 7 Bell Yard, London,England WC2A 2JR.